These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11020574)

  • 41. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study.
    Mahdi H; Elshaikh MA; DeBenardo R; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; Moslemi-Kebria M
    Gynecol Oncol; 2015 May; 137(2):239-44. PubMed ID: 25641568
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
    Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP
    Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.
    Slomovitz BM; Burke TW; Eifel PJ; Ramondetta LM; Silva EG; Jhingran A; Oh JC; Atkinson EN; Broaddus RR; Gershenson DM; Lu KH
    Gynecol Oncol; 2003 Dec; 91(3):463-9. PubMed ID: 14675663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
    Goldberg H; Miller RC; Abdah-Bortnyak R; Steiner M; Yildiz F; Meirovitz A; Villà S; Poortmans PM; Azria D; Zidan J; Ozsahin M; Abacioglu U; Gold DG; Amit A; Lavie O; Atahan IL; Kuten A;
    Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study.
    Sutton G; Axelrod JH; Bundy BN; Roy T; Homesley HD; Malfetano JH; Mychalczak BR; King ME
    Gynecol Oncol; 2005 Jun; 97(3):755-63. PubMed ID: 15913742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early-stage Uterine Pure and Mixed Clear Cell Carcinoma: Outcomes and Recurrence With and Without Adjuvant Therapy.
    Chang-Halpenny CN; Natarajan S; Hwang-Graziano JM
    Am J Clin Oncol; 2018 Apr; 41(4):371-378. PubMed ID: 26950465
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
    Kelly MG; O'Malley D; Hui P; McAlpine J; Dziura J; Rutherford TJ; Azodi M; Chambers SK; Schwartz PE
    Gynecol Oncol; 2004 Dec; 95(3):469-73. PubMed ID: 15581948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma.
    Lindahl B; Persson J; Ranstam J; Willén R
    Anticancer Res; 2010 Sep; 30(9):3727-30. PubMed ID: 20944161
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
    Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
    Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-dose rate brachytherapy for Stage I/II papillary serous or clear cell endometrial cancer.
    DuBeshter B; Estler K; Altobelli K; McDonald S; Glantz C; Angel C
    Gynecol Oncol; 2004 Aug; 94(2):383-6. PubMed ID: 15297176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome.
    Faratian D; Stillie A; Busby-Earle RM; Cowie VJ; Monaghan H
    Int J Gynecol Cancer; 2006; 16(3):972-8. PubMed ID: 16803471
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy.
    Huh WK; Powell M; Leath CA; Straughn JM; Cohn DE; Gold MA; Falkner CA; Carey DE; Herzog T; Fowler JM; Partridge EE; Kilgore LC; Alvarez RD
    Gynecol Oncol; 2003 Dec; 91(3):470-5. PubMed ID: 14675664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
    Thomas MB; Mariani A; Cliby WA; Keeney GL; Podratz KC; Dowdy SC
    Gynecol Oncol; 2007 Nov; 107(2):190-3. PubMed ID: 17825394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Uterine papillary serous carcinoma: patterns of failure and survival.
    Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
    Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma.
    Mundt AJ; Murphy KT; Rotmensch J; Waggoner SE; Yamada SD; Connell PP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1154-60. PubMed ID: 11483324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.
    Hamilton CA; Cheung MK; Osann K; Chen L; Teng NN; Longacre TA; Powell MA; Hendrickson MR; Kapp DS; Chan JK
    Br J Cancer; 2006 Mar; 94(5):642-6. PubMed ID: 16495918
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome.
    Lim P; Al Kushi A; Gilks B; Wong F; Aquino-Parsons C
    Cancer; 2001 Feb; 91(4):752-7. PubMed ID: 11241243
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked Stage I, II, and III ovarian cancer.
    Fyles AW; Thomas GM; Pintilie M; Ackerman I; Levin W
    Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):543-9. PubMed ID: 9635700
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study.
    Lin JF; Muñiz K; Sukumvanich P; Gehrig P; Beriwal S; Kelley JL; Edwards RP; Olawaiye AB
    BJOG; 2016 Oct; 123(11):1846-52. PubMed ID: 26537059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients.
    Grice J; Ek M; Greer B; Koh WJ; Muntz HG; Cain J; Tamimi H; Stelzer K; Figge D; Goff BA
    Gynecol Oncol; 1998 Apr; 69(1):69-73. PubMed ID: 9571001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.